Navigation Links
China Sky One Medical, Inc. Obtains Production Rights for Two Additional Drugs
Date:12/16/2008

HARBIN, China, Dec. 16 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that it successfully obtained the production approval from the State Food and Drug Administration (SFDA) in China for two additional drugs: Sodium Cromoglicate Eye Drops for the treatment of allergic conjunctivitis and Ftibamzone Liniment for the treatment of herpes and fungal skin infection. The company is planning to launch the production of these two new approved drugs early next year.

Including Sodium Cromoglicate Eye Drops and Ftibamzone Liniment, China Sky One Medical has now received SFDA approval for a total of 15 new drugs in 2008.

    -- Sodium Ferulate injection for the treatment of cardiovascular disease;
    -- Compound Naphazoline spray is for the treatment of rhinopathy;
    -- Naphazoline Hydrochloride Chlorpheniramine Maleate and Benzalkonium
       Bromide spray for the treatment of rheumatic diseases;
    -- Doxofylline injection for the treatment of asthma and bronchitis;
    -- Oxymetazoline Hydrochloride nasal drops for the treatment of acute and
       chronic rhinitis, sinusitis and allergic rhinitis;
    -- Taurine eye drops for the treatment of acute and chronic
       conjunctivitis;
    -- Tobramycin eye drops for the treatment of acute infection on eyelids;
    -- Compound Zinc Sulfate eye drops for the treatment of acute and chronic
       conjunctivitis and trachoma;
    -- Ofloxacin suppositories for the treatment for bactericidal vaginitis
       and Oflcoxacin gel for the treatment of bactericidal colpitis;
    -- Nasal drops for the treatment of allergic rhinitis and sinusitis;
    -- Tinea Liniment for the treatment of athlete's foot (tinea pedis), hand
       ringworm (tinea manus), jock itch (tinea cruris) and fungal skin
       infection (tinea versicolor); and
    -- Skincare cream for the treatment of skin diseases such as acne, bottle
       nose, chromophytosis and vitiligo.

"We are proud to have obtained production approval for 15 new drugs in 2008 and see this as an outstanding achievement for China Sky One," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "These drugs treat a variety of illnesses and we are excited about their market potential. We are confident that strong results from our R&D efforts will lead to more drug approvals in 2009, which will further enhance our sales performance."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Company Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Mr. Yu-Bo Hao, CFO
     Tel:   +86-451-5399-4069
     Email: china_sky_one@yahoo.cn

    Investor Relations Contact:
     CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Chinas 1-child policy could backfire on its elderly
2. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. Bridgetech Announces Addition of the Agency for Healthcare Research and Quality as Content Provider in its Development of a Healthcare Web Portal in China
5. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
6. China Bionanometer Industries Corporation Promotes New Cosmetics Product Line in China
7. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
8. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
9. Supplier Assessments to Help Buyers Identify Reliable China Exporters
10. Study shows lead-based paint problem isnt isolated to China
11. Bracco Announces Initiative to Save Children in China at 2007 Annual Meeting of CGI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Representatives of CHA Fertility Centers ... member of their staff, Dr. Joshua J. Berger. As of May 2016, Dr. ... world-renowned facility. , Dr. Berger has received recognition for his research, his teaching and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Horizon Blue Cross Blue Shield ... relief from the crushing burden of sky-high health care costs, Superior Court of ... ruling ( http://www.judiciary.state.nj.us/opinions/a2913-15a2929-15.pdf ) the court provided some analysis of the contracts ...
(Date:6/23/2016)... ... ... As part of an ongoing commitment to encourage living a healthy and ... BCBSNJ) have teamed up with New Jersey native and PGA Tour member Morgan Hoffmann ... lifestyle. , Through Healthy Steps NJ, Hoffmann will share a series of health education ...
(Date:6/23/2016)... ... ... A key metric of this success is the popularity of the Leafedin.org service ... areas that lack the kind of technology and networking framework that LeafedIn.org provide, where ... the marijuana industry, no matter how small or large, and more importantly no matter ...
(Date:6/23/2016)... ... June 23, 2016 , ... King Kullen’s Shop OnLine, the ... to yet another location: Garden City Park. This is the fourth store to be ... grocery delivery service is offered by King Kullen and allows customers to place orders ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology: